Rapid Ngn2-induction of excitatory neurons from hiPSC-derived neural progenitor cells.

paper Cited Public

Authors: Ho, Seok-Man; Hartley, Brigham J; Tcw, Julia; Beaumont, Michael; Stafford, Khalifa; Slesinger, Paul A; Brennand, Kristen J
Year: 2016
Journal: Methods (San Diego, Calif.)
PMID: 26626326
DOI: 10.1016/j.ymeth.2015.11.019
PMCID: PMC4860098

Fig. 1

Scheme of Ngn2-neuronal induction from human NPCs and the accelerated neuronal morphology of Ngn2-NPCs. (A) Schematic of mNgn2 and hNGN2 neuronal induction, starting from hiPSC-derived NPCs. (B) Representative bright-field images of hiPSCs, NPCs and mNgn2-induced neurons. Scale bar 100 μm. (C) Timeline of mNgn2 and hNGN2-neuronal induction strategy. (D) GFP images of NPCs transduced with GFP-PuroR lentivirus (images taken before and 24 h after doxycycline treatment). Scale bar 100 μm. (E) FACS quantification of the percentage of GFP-positive cells across ten NPC lines transduced with hNGN2-eGFP-PuroR (presented as the average of three NPC lines each from two controls, and one NPC line each from a third control as well as three schizophrenia patients). (F) GFP images of live GFP-, mNgn2- and hNGN2-transduced NPCs at various induction time points, showing that Ngn2-NPCs acquire neuronal morphology faster than GFP-NPCs. Scale bar 50 μm. (G) Averaged MAP2AB fluorescent intensity of GFP-, mNgn2 and hNGN2-induced neurons at three weeks induction. Error bars are SEM (Standard Error of the Mean). *p < 0.05, **p < 0.01, ***p < 0.001.

Fig. 2

Accelerated increase in MAP2AB protein and RNA by Ngn2-transduction. (A) Representative images of mNgn2-induced neurons and GFP-NPCs at two weeks immunostained with neuronal dendrite marker MAP2AB (red), GFP (green) and DAPI-stained nuclei (blue). Scale bar 30 μm. (B) Averaged MAP2AB fluorescent intensity of GFP-NPCs and mNgn2-induced neurons at two weeks induction. MAP2AB intensity was normalized to total DAPI-positive nuclei per image, and further standardized to GFP-NPCs; mNgn2-induced neurons showed a 1.3-fold increase in MAP2AB intensity over GFP-NPCs. (C) Real-time qPCR analysis of MAP2AB mRNA expression from GFP-NPCs and mNgn2-induced neurons at two weeks of age. The expression level is normalized to GAPDH, and further standardized to GFP-NPCs; mNgn2-neurons showed 2.4-fold increase in MAP2AB. (D) Representative images of two-week-old and three-week-old mNgn2-induced neurons stained with MAP2AB (red) and DAPI (blue). Scale bar 30 μm. (E) Averaged MAP2AB fluorescent intensity of two-week-old and three-week-old mNgn2-induced neurons, normalized to two-week-old mNgn2-induced neurons; there was a 1.35-fold increased MAP2AB intensity in three-week-old mNgn2-induced neurons. Error bars are SEM (Standard Error of the Mean). *p < 0.05, **p < 0.01, ***p < 0.001.

Fig. 3

Evoked activity recorded from Ngn2-induced neurons. (A) Voltage clamp recording shows putative voltage-gated Na+ (inward) and K+ (outward) currents. Voltage pulses shown below (−100 to +70 mV). Holding potential was −70 mV. (B) Current clamp recording from the same neuron shows evoked action potentials. Dashed line indicates −60 mV. Current injection pulses shown below (−16 pA to 48 pA).

Fig. 4

Accelerated synaptic differentiation of Ngn2-induced neurons by neuronal induction. (A) Representative images of mNgn2-neurons and GFP-NPCs at three weeks, immunostained with presynaptic marker SYN1 (red) and MAP2AB (magenta). Scale bar 4 μm. (B) SYN1 puncta count, normalized to MAP2AB+ area, of mNgn2-induced neurons and GFP-NPCs at three weeks (gradual doxycycline withdrawal from day 2). The SYN1 puncta ratio was increased 1.9-fold relative to matched GFP-NPCs. (C) Real-time qPCR analysis of SYN1, vGLUT1, vGLUT2 and PSD95 mRNA expression from GFP-NPCs and mNgn2-induced neurons at three weeks, normalized to GAPDH, relative to GFP-NPCs. mNgn2-neurons showed increased SYN1 (2.3-fold), vGLUT1 (4.5-fold), vGLUT2 (3.8-fold); there no significant difference in PSD95 expression. (D) qPCR analysis of TH, GAD67, vGAT, TPH1, GFAP and S100β mRNA expression between three-week-old mNgn2-induced neurons and 6-week-old hiPSC forebrain (FB) neurons derived by directed differentiation; Ngn2-induced neurons showed decreased TH (6.3-fold), GAD67 (1.5-fold), comparably low levels of vGAT and TPH1, and decreased GFAP (13.6-fold) and S100β(3.2-fold) expression relative to 6-week-old forebrain neurons. (E) Representative images of 3-week-old mNgn2-induced neurons and PuroR-NPCs, stained with the dopaminergic marker TH, the GABAergic marker GAD65/67 and the astrocyte marker GFAP. DAPI-stained nuclei (blue). Scale bar 30 μm. (F) Representative bright-field images of 3-week-old hNGN2-induced neurons treated with 0 M, 10 nM, 50 nM, 100 nM and 1 μM Ara-C from days 6–20. Scale bar 30 μm. (G) Representative images of 3-week–old hNGN2-induced neurons (from two independent controls) treated with 0 nM, 10 nM, 50 nM, and 100 nM Ara-C from days 6–20, stained with the replication marker Ki67. DAPI-stained nuclei (blue). Scale bar 30 μm. (H) Percentage of Ki67-positive cells in three-week-old Ngn2-induced neuron populations treated with between 0 and 100 nM Ara-C. Error bars are SEM. *p < 0.05, **p < 0.01, ***p < 0.001.

Fig. 5

Transient Ngn2 is sufficient to generate induced neurons. (A) Timeline of mNgn2-neuronal induction strategy with different doxycycline lengths. Doxycycline was withdrawn at day two (D2), day eight (D8), day fourteen (D14) or not at all (No W/D). (B) Representative images of three-week-old mNgn2-induced neurons immunostained with MAP2AB (red) and DAPI (blue). Scale bar 30 μm. (C) Average MAP2AB fluorescent intensity at three weeks. (D) Representative images mNgn2-induced neurons immunostained with the presynaptic marker SYN1 (red) and MAP2AB (magenta). Scale bar 4 μm. (E) SYN1 puncta count, normalized to MAP2AB+ area at three-weeks. (F) Real-time qPCR analysis of SYN1, vGLUT1, vGLUT2 and PSD95 mRNA expression at three-weeks. Error bars are SEM. *p < 0.05, **p < 0.01, ***p < 0.001.

Fig. 6

Electrical activity of Ngn2-induced neurons from NPCs. (A) 5-min MEA raster plot of spontaneous activity from a neural network of 14-day-old neurons, with 0-days (left panel) or 14-days (right panel) doxycycline treatment to induce mNgn2 expression. The response over multiple electrodes is a measurement of network connectivity. Each thin black line is representative of an action potential. Bursts of electrical activity are indicated with solid blue blocks. (B) The percentage of active electrodes per well (left panel) or percentage of spikes in bursts (right panel) following either 0 days (white bar), 2 days (pink bar), 8 days (light red) or 14 days (dark red) of doxycycline treatment to induce mNgn2 expression in 14-day-old neurons. (C) Total number of spikes (left panel) or mean firing rate (Hz) (right panel) following treatment with vehicle control (DMSO), picrotoxin (PTX), 6-cyano-7-nitroquinoxaline-2,3-dion (CNQX) and tetrodotoxin (TTX) on 21-day-old hNGN2-neurons. Error bars are SEM. *p < 0.05, **p < 0.01, ***p < 0.001.

Fig. 7

Inter-individual efficiencies in Ngn2-induction between NPC lines. Representative bright-field images of hNGN2-neurons from six individuals (three controls and three schizophrenia patients) over three independent experiments. Varying the initial seeding density of individual NPC lines (NPC plating densities inset) is required if achieving a consistent neuronal density at the end-point is desired.

#	Section	Preview
20	2. Material and methods — 2.2. Neuronal induction (Fig. 1A–C) — 2.2.2. Lentiviral transduction — Day-1: Transduction	Note: We recently generated TetO-hNGN2-P2A-PuroR and TetO-hNGN2-P2A-eGFP-T2A-PuroR lentiviral…
21	2. Material and methods — 2.2. Neuronal induction (Fig. 1A–C) — 2.2.2. Lentiviral transduction — Day-1: Transduction	To transduce NPCs, the media was aspirated and replaced with NPC medium containing the lentiviruses.…
22	2. Material and methods — 2.2. Neuronal induction (Fig. 1A–C) — 2.2.2. Lentiviral transduction — Day-1: Transduction	Spinfection was used to increase transduction efficiency [36]. The 24-well plate was placed in the…
23	2. Material and methods — 2.2. Neuronal induction (Fig. 1A–C) — 2.2.3. Doxycycline addition and puromycin selection — Day 0: Doxycycline treatment	Doxycycline (Sigma, #D9891) was diluted (1 μg/ml) in NPC medium and 500 μl added to each well of a…
24	2. Material and methods — 2.2. Neuronal induction (Fig. 1A–C) — 2.2.3. Doxycycline addition and puromycin selection — Day 0: Doxycycline treatment	24 h following doxycycline addition, GFP fluorescence can be observed in most NPCs (usually >90%,…
25	2. Material and methods — 2.2. Neuronal induction (Fig. 1A–C) — 2.2.3. Doxycycline addition and puromycin selection — Day 1: Puromycin selection	Media was replaced with fresh NPC medium containing 1 μg/ml puromycin (Sigma, #P7255) and 1 μg/ml…
26	2. Material and methods — 2.2. Neuronal induction (Fig. 1A–C) — 2.2.4. Puromycin withdrawal and switch to neuron medium — Day 2: Puromycin withdrawal and switch to neuron medium	Media was replaced with neuron medium (Table 1) containing 1 μg/ml doxycycline (500 μl per well of…
27	2. Material and methods — 2.2. Neuronal induction (Fig. 1A–C) — 2.2.4. Puromycin withdrawal and switch to neuron medium — Day 4–20: Regular half medium changes	Doxycycline can be withdrawn at any time during the protocol. We recommend a 50% reduction in the…
28	2. Material and methods — 2.2. Neuronal induction (Fig. 1A–C) — 2.2.4. Puromycin withdrawal and switch to neuron medium — Day 4–20: Regular half medium changes	To achieve this, 250 μl of medium per well was removed and replaced with 280 μl of fresh neuron…
29	2. Material and methods — 2.2. Neuronal induction (Fig. 1A–C) — 2.2.4. Puromycin withdrawal and switch to neuron medium — Day 6–20: Ara-C treatment	Neuron medium can be supplemented with 50 nM Cytosineβ-D-arabinofuranoside hydrochloride (Ara-C)…
30	2. Material and methods — 2.3. Analysis of mNgn2- and hNGN2-induced neurons — 2.3.1. Immunostaining of mNgn2- and hNGN2-neurons	For immunostaining, neurons were first cooled to room temperature for 5 min. 250 μl of medium was…
31	2. Material and methods — 2.3. Analysis of mNgn2- and hNGN2-induced neurons — 2.3.1. Immunostaining of mNgn2- and hNGN2-neurons	Following aspiration of the PFA/medium mix, ice-cold blocking/ permeabilization buffer (PBS…
32	2. Material and methods — 2.3. Analysis of mNgn2- and hNGN2-induced neurons — 2.3.1. Immunostaining of mNgn2- and hNGN2-neurons	During blocking and permeabilization, the primary antibody (Table 2) solution was prepared in…
33	2. Material and methods — 2.3. Analysis of mNgn2- and hNGN2-induced neurons — 2.3.1. Immunostaining of mNgn2- and hNGN2-neurons	Following incubation, the primary antibody solution was removed and the wells were washed with…
34	2. Material and methods — 2.3. Analysis of mNgn2- and hNGN2-induced neurons — 2.3.1. Immunostaining of mNgn2- and hNGN2-neurons	Neurons were then incubated with secondary antibody (Table 2) prepared in ice-cold…
35	2. Material and methods — 2.3. Analysis of mNgn2- and hNGN2-induced neurons — 2.3.2. Preparation of neurons for confocal microscopy	AquaPolymount mounting solution (Polysciences Inc., #18606-20) was equilibrated to room temperature.…
36	2. Material and methods — 2.3. Analysis of mNgn2- and hNGN2-induced neurons — 2.3.3. Analysis for MAP2AB intensity and SYN1 puncta	mNgn2-induced neurons and control GFP transduced NPCs at two or three weeks of culture were…
37	2. Material and methods — 2.3. Analysis of mNgn2- and hNGN2-induced neurons — 2.3.3. Analysis for MAP2AB intensity and SYN1 puncta	mNgn2-induced neurons and GFP-NPCs at two and three weeks of culture were immunostained with SYN1…
38	2. Material and methods — 2.4. Quantitative Real Time PCR	Cells were harvested with RNABee (Amsbio, CS-105B) at room temperature for 5 min. Lysates were…
39	2. Material and methods — 2.4. Quantitative Real Time PCR	RNA was treated with DNAse kit (Ambion, AM1907) and quantified with a Nanodrop. 1 μg of total RNA…

Name	Type
24-well plate local	cohort
accutase	drug
action potential firing	phenotype
Allen Brain Span Atlas local	cohort
AquaPolymount mounting solution local	drug
Ara-C	drug
artificial cerebral spinal fluid (ACSF) local	drug
Ascl1	gene
astrocytes	phenotype
astroglia	anatomy
blocking/permeabilization buffer local	drug
brain development	phenotype
Brn2	gene
Ca2+	drug
calcium chloride	drug
Cases_and_controls local	cohort
cDNA	drug
cell attachment local	phenotype
chloroform	drug
cholinergic neurons	phenotype
CNQX	drug
coating mixture local	drug
control GFP transduced NPCs local	cohort
controls	cohort
cortex	anatomy
culture medium	drug
Cytosineβ-D-arabinofuranoside hydrochloride local	drug
DAPI	drug
DEPC-treated water local	drug
Dlg4	gene
DMEM	drug
DNAse kit (Ambion, AM1907) local	drug
donkey serum	drug
dopaminergic neurons	anatomy
doxycycline	drug
Dulbecco's Modified Eagle Medium	drug
early fetal human cortical tissue local	anatomy
eGFP	drug
EGTA	drug
enhanced neuronal maturation local	phenotype
Fast SYBR green master mix local	drug
fetal forebrain tissue local	anatomy
forebrain	anatomy
forebrain NPCs local	anatomy
GABA	phenotype
GABAergic neuronal differentiation local	phenotype
GAD1	gene
GAD65/67 local	phenotype
GFAP	gene
GFP	drug
glucose	drug
glutamatergic neurons	phenotype
growth factors	drug
HEK293T cells local	cohort
HEPES	drug
hiPSC-based induction local	cohort
hiPSCs local	drug
hNGN2 local	variant
hNGN2-induced neurons local	cohort
hNGN2-neurons local	cohort
induced neurons	phenotype
Isl1	gene
isopropanol	drug
K+ channel local	drug
Ki67-positive replicative cells local	phenotype
laminin	drug
lentivirus	drug
LHX3	gene
liquid nitrogen	drug
magnesium chloride	drug
MAP2	gene
MAP2AB	gene
MAP2AB local	phenotype
matrigel	drug
MEA plate local	cohort
Mg2+	drug
miR-124	drug
miR-9	drug
mNgn2 local	variant
mNgn2-induced neurons local	cohort
mNgn2-induced neurons local	phenotype
motor neuron identity local	phenotype
motor neurons local	phenotype
mouse brain	anatomy
Myt1l	gene
Na2ATP	drug
Na3GTP local	drug
Na+ channel local	drug
NaHCO3	drug
Nanodrop	drug
Neural progenitor cells (NPC) local	cohort
neurite growth local	phenotype
neuroblast stage local	phenotype
NEUROD1	gene
NEUROG2	gene
neurogenesis	phenotype
neuronal activity	phenotype
neuronal differentiation	phenotype
neuronal fate	phenotype
neuronal induction local	phenotype
neuronal morphology	phenotype
neuron medium local	drug
neurons local	drug
neurons	phenotype
Neuropsychiatric_disorders local	phenotype
Ngn2	gene
Ngn family local	gene
non-neuronal cell proliferation local	phenotype
NPC	drug
NPC-based induction local	cohort
NPC line local	cohort
NPC lines local	cohort
NPC medium local	drug
NPCs	cohort
NSB1442-4-3 local	cohort
NSB2513-1-4 local	cohort
NSB2607-1-4 local	cohort
NSB2607-3-1 local	cohort
NSB2607-4-1 local	cohort
NSB553-1-1 local	cohort
NSB553-2-3 local	cohort
NSB553-3-C local	cohort
NSB581-1-2 local	cohort
NSB690-1-4 local	cohort
paraformaldehyde	drug
PBSCa2+Mg2+ local	drug
PFA/medium mix local	drug
picrotoxin	drug
polyethylenimine	drug
poly-l-ornithine	drug
poly-ornithine	drug
postsynaptic maturation local	phenotype
potassium chloride	drug
potassium-D-gluconate local	drug
presynaptic maturation local	phenotype
primary antibody	drug
proliferative cells	phenotype
PSD95	gene
psychiatric disorders	phenotype
PTX	drug
puromycin	drug
PuroR local	gene
reduced dendritic arborization local	phenotype
reduced synaptic density local	phenotype
resting potential local	phenotype
RNA	drug
RNABee local	drug
RNAse-free 75% ethanol local	drug
rtTa	drug
S100B local	gene
schizophrenia	phenotype
secondary antibody	drug
six independent individuals local	cohort
six-week-old hiPSC forebrain neurons local	cohort
Slc17a6	gene
Slc17a7	gene
SLC32A1	gene
small molecules	drug
sodium chloride	drug
sodium creatine phosphate local	drug
sodium phosphate local	drug
SOX11	gene
spinal cord	anatomy
Spinfection local	drug
study cohort	cohort
Superscript III reverse transcription kit (ThermoFisher Scientific, 11752-050) local	drug
SYN1	gene
synaptogenesis	phenotype
TetO-hNGN2-P2A-eGFP-T2A-PuroR local	drug
TetO-hNGN2-P2A-PuroR local	drug
TetO-mNgn2-P2A-PuroR local	drug
tetrodotoxin	drug
Th	gene
three-week-old mNgn2-induced neurons local	cohort
TPH1	gene
transduction efficiency local	phenotype
Triton-X	drug
TTX	drug
vGLUT1	gene
vGLUT2	gene
viral medium local	drug
VSVG local	gene

Citation	PMID	DOI	Status
Beaudoin, GM, Nat Protoc, 2012, Culturing pyramidal neurons from the early postnatal mouse hippocampus and cortex	22936216	10.1038/nprot.2012.099	Cited
Black, JE, Am J Psychiatry, 2004, Pathology of layer V pyramidal neurons in the prefrontal cortex of patients with schizophrenia	15056523	10.1176/appi.ajp.161.4.742	Cited
Brennand, KJ et al., Biol Psychiatry, 2014, Modeling heterogeneous patients with a clinical diagnosis of schizophrenia with induced pluripotent stem cells	24331955	10.1016/j.biopsych.2013.10.025	Cited
Brennand, KJ, Nature, 2011, Modelling schizophrenia using human induced pluripotent stem cells	21490598	10.1038/nature09915	Cited
Brennand, Mol Psychiatry, 2014, Phenotypic differences in hiPSC NPCs derived from patients with schizophrenia	24686136	10.1038/mp.2014.22	Cited
Busskamp, V, Mol Syst Biol, 2014, Rapid neurogenesis through transcriptional activation in human stem cells	25403753	10.15252/msb.20145508	Cited
Chambers, SM, Nat Biotechnol, 2009, Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling	19252484	10.1038/nbt.1529	Cited
Chanda, S, Stem Cell Rep, 2014, Generation of induced neuronal cells by the single reprogramming factor ASCL1	25254342	10.1016/j.stemcr.2014.05.020	Cited
Espuny-Camacho, I, Neuron, 2013, Pyramidal neurons derived from human pluripotent stem cells integrate efficiently into mouse brain circuits in vivo	23395372	10.1016/j.neuron.2012.12.011	Cited
Glantz, LA et al., Arch Gen Psychiatry, 2000, Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia	10632234	10.1001/archpsyc.57.1.65	Cited
Heinrich, C, PLoS Biol, 2010, Directing astroglia from the cerebral cortex into subtype specific functional neurons	20502524	10.1371/journal.pbio.1000373	Cited
Hester, ME, Mol Ther, 2011, Rapid and efficient generation of functional motor neurons from human pluripotent stem cells using gene delivered transcription factor codes	21772256	10.1038/mt.2011.135	Cited
Kamiya, A, Nat Cell Biol, 2005, A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development	16299498	10.1038/ncb1328	Cited
Kvajo, M, Proc Natl Acad Sci USA, 2008, A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition	18458327	10.1073/pnas.0802615105	Cited
Lee, SK, Neuron, 2003, Synchronization of neurogenesis and motor neuron specification by direct coupling of bHLH and homeodomain transcription factors	12797958	10.1016/s0896-6273(03)00296-4	Cited
Liu, ML, Nat Commun, 2013, Small molecules enable neurogenin 2 to efficiently convert human fibroblasts into cholinergic neurons	23873306	10.1038/ncomms3183	Cited
Ma, YC, Neuron, 2008, Regulation of motor neuron specification by phosphorylation of neurogenin 2	18400164	10.1016/j.neuron.2008.01.037	Cited
Marchetto, M, Cell, 2010, A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells	21074045	10.1016/j.cell.2010.10.016	Cited
Mariani, J, Proc Natl Acad Sci USA, 2012, Modeling human cortical development in vitro using induced pluripotent stem cells	22761314	10.1073/pnas.1202944109	Cited
Miller, JA, Nature, 2014, Transcriptional landscape of the prenatal human brain	24695229	10.1038/nature13185	Cited
Mizuguchi, R, Neuron, 2001, Combinatorial roles of olig2 and neurogenin2 in the coordinated induction of pan-neuronal and subtype-specific properties of motoneurons	11567615	10.1016/s0896-6273(01)00413-5	Cited
Molyneaux, BJ et al., Nat Rev Neurosci, 2007, Neuronal subtype specification in the cerebral cortex	17514196	10.1038/nrn2151	Cited
Muotri, AR, Nature, 2010, L1 retrotransposition in neurons is modulated by MeCP2	21085180	10.1038/nature09544	Cited
Nicholas, C, Cell Stem Cell, 2013, Functional maturation of hPSC-derived forebrain interneurons requires an extended timeline and mimics human neural development	23642366	10.1016/j.stem.2013.04.005	Cited
O’Doherty, U, J Virol, 2000, Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding	11024136	10.1128/jvi.74.21.10074-10080.2000	Cited
Pang, ZP, Nature, 2011, Induction of human neuronal cells by defined transcription factors	21617644	10.1038/nature10202	Cited
Pletnikov, Mol Psychiatry, 2007, Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia	17848917	10.1038/sj.mp.4002079	Cited
Ross, SE, Neuron, 2003, Basic helix–loop–helix factors in cortical development	12848929	10.1016/s0896-6273(03)00365-9	Cited
Roybon, L, Cereb Cortex, 2010, GABAergic differentiation induced by Mash1 is compromised by the bHLH proteins Neurogenin2, NeuroD1, and NeuroD2	19767311	10.1093/cercor/bhp187	Cited
Sequerra, E et al., Development (Cambridge, England), 2013, Adult neural stem cells: plastic or restricted neuronal fates	23900539	10.1242/dev.093096	Cited
Shi, Y et al., Nat Neurosci, 2012, Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses	22306606	10.1038/nn.3041	Cited
Sun, Y, Cell, 2001, Neurogenin promotes neurogenesis and inhibits glial differentiation by independent mechanisms	11239394	10.1016/s0092-8674(01)00224-0	Cited
Thoma, EC, PLoS One, 2012, Ectopic expression of neurogenin 2 alone is sufficient to induce differentiation of embryonic stem cells into mature neurons	22719915	10.1371/journal.pone.0038651	Cited
Tiscornia, G et al., Nat Protoc Electron Ed, 2006, Production and purification of lentiviral vectors	17406239	10.1038/nprot.2006.37	Cited
Topol, A et al., J Vis Exp: JoVE, 2015, A guide to generating and using hiPSC derived NPCs for the study of neurological diseases	25742222	10.3791/52495	Cited
Yoo, A, Nature, 2011, MicroRNA-mediated conversion of human fibroblasts to neurons	21753754	10.1038/nature10323	Cited
Yu, X et al., Tissue Eng, 1999, A laminin and nerve growth factor-laden three-dimensional scaffold for enhanced neurite extension	10477852	10.1089/ten.1999.5.291	Cited
Yuan, L et al., Arch Biochem Biophys, 2014, Neurogenins in brain development and disease: an overview	24950022	10.1016/j.abb.2014.05.028	Cited
Zhang, Y, Neuron, 2013, Rapid single-step induction of functional neurons from human pluripotent stem cells	23764284	10.1016/j.neuron.2013.05.029	Cited

In this knowledge base

Title	Year	PMID
Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells?	2018	29897633
Evaluating Synthetic Activation and Repression of Neuropsychiatric-Related Genes in hiPSC-Derived NPCs, Neurons, and Astrocytes.	2017	28757163

External

Title	Authors	Journal	Year	Link
3D genetic architecture of schizophrenia risk across three neuronal subtypes.	Powell SK et al.	—	2026	→
A co-culture model of dopaminergic and glutamatergic neurons derived from patients with idiopathic schizophrenia reveals a hypodopaminergic phenotype.	Hartmann SM et al.	—	2026	→
Functional implications of polygenic risk for schizophrenia in human neurons.	Michael Deans PJ et al.	—	2026	→
Retinoic acid signaling regulates astrocyte reactivity by modulating MAPK/NF-κB pathways and mitochondrial integrity.	Yoo SH et al.	—	2026	→
Temporal proteomic and phosphoproteomic dynamics during neuronal differentiation in the reference iPSC line KOLF2.1J.	Hao Y et al.	—	2026	→
Transcriptomic and phenotypic convergence of neurodevelopmental disorder risk genes in vitro and in vivo.	Fernandez Garcia M et al.	—	2026	→
Uncovering NMDA receptor-mediated high firing activity in excitatory human neurons.	Gameiro-Ros I et al.	—	2026	→
ABCA7 variants impact phosphatidylcholine and mitochondria in neurons.	von Maydell D et al.	—	2025	→
An antisense oligonucleotide-based strategy to ameliorate cognitive dysfunction in the 22q11.2 Deletion Syndrome.	Thakur P et al.	—	2025	→
Cell culture research in aging and Alzheimer's disease: The strategic use/reuse of untreated controls and savings people's tax dollars.	Kshirsagar S et al.	—	2025	→
Drug treatment alters performance in a neural microphysiological system of information processing.	Watmuff B et al.	—	2025	→
Harnessing Intelligence from Brain Cells In Vitro.	Kagan BJ et al.	—	2025	→
Human CLOCK enhances neocortical function.	Liu Y et al.	—	2025	→
Human-Induced Pluripotent Stem Cells (iPSCs) for Disease Modeling and Insulin Target Cell Regeneration in the Treatment of Insulin Resistance: A Review.	Thiab S et al.	—	2025	→
Integrated multi-omic characterizations of the synapse reveal RNA processing factors and ubiquitin ligases associated with neurodevelopmental disorders.	Mei Y et al.	—	2025	→
K<sub>V</sub>7.2 channel dysfunction delays neuronal maturation and undermines early network development in a hiPSC model of KCNQ2-DEE.	Rosa F et al.	—	2025	→
Multiscale proteomic modeling reveals protein networks driving Alzheimer's disease pathogenesis.	Wang E et al.	—	2025	→
Neurodegenerative disease-associated microRNAs acting as signaling molecules modulate CNS neuron structure and viability.	Kumbol V et al.	—	2025	→
Neuron-reactive KIR<sup>+</sup>CD8<sup>+</sup> T cells display an encephalitogenic transcriptional program in autoimmune encephalitis.	Perriot S et al.	—	2025	→
Phenotypic complexities of rare heterozygous neurexin-1 deletions.	Fernando MB et al.	—	2025	→
Precision medicine approach for in vitro modeling and computational screening of anti-epileptic drugs in pediatric epilepsy patients with SCN2A (R1629L) mutation.	Kim J et al.	—	2025	→
Pulsed electromagnetic stimulation promotes neuronal maturation by up-regulating cholesterol biosynthesis.	Chen P et al.	—	2025	→
Subcellular proteomics and iPSC modeling uncover reversible mechanisms of axonal pathology in Alzheimer's disease.	Cai Y et al.	—	2025	→
The Life and Times of Brain Autophagic Vesicles.	Gambarotto L et al.	—	2025	→
Aberrant neuronal connectivity and network activity of neurons derived from patients with idiopathic schizophrenia.	Heider J et al.	—	2024	→
A comprehensive protocol for efficient differentiation of human NPCs into electrically competent neurons.	Romito E et al.	—	2024	→
Activity-Dependent Transcriptional Program in NGN2+ Neurons Enriched for Genetic Risk for Brain-Related Disorders.	Ma Y et al.	—	2024	→
An integrated in vitro human iPSCs-derived neuron and in vivo animal approach for preclinical screening of anti-seizure compounds.	Zhao C et al.	—	2024	→
Concerted transcriptional regulation of the morphogenesis of hypothalamic neurons by ONECUT3.	Zupančič M et al.	—	2024	→
Deciphering the Pathophysiological Mechanisms Underpinning Myoclonus Dystonia Using Pluripotent Stem Cell-Derived Cellular Models.	Li Z et al.	—	2024	→
Defined co-cultures of glutamatergic and GABAergic neurons with a mutation in DISC1 reveal aberrant phenotypes in GABAergic neurons.	Heider J et al.	—	2024	→
ePRINT: exonuclease assisted mapping of protein-RNA interactions.	Hawkins S et al.	—	2024	→
Generation of a stably transfected mouse embryonic stem cell line for inducible differentiation to excitatory neurons.	Gu J et al.	—	2024	→
Human stem cell-based models to study synaptic dysfunction and cognition in schizophrenia: A narrative review.	Santarriaga S et al.	—	2024	→
Human stem cell-derived neurons and astrocytes to detect novel auto-reactive IgG response in immune-mediated neurological diseases.	Mathias A et al.	—	2024	→
Probing the molecular and cellular pathological mechanisms of schizophrenia using human induced pluripotent stem cell models.	Sebastian R et al.	—	2024	→
Senescent Astrocytes Derived from Human Pluripotent Stem Cells Reveal Age-Related Changes and Implications for Neurodegeneration.	Kim D et al.	—	2024	→
Supra- and sub-threshold intracellular-like recording of 2D and 3D neuronal networks using nanopillar electrode arrays.	Shukla S et al.	—	2024	→
Upregulated GIRK2 Counteracts Ethanol-Induced Changes in Excitability and Respiration in Human Neurons.	Prytkova I et al.	—	2024	→
β-Amyloid species production and tau phosphorylation in iPSC-neurons with reference to neuropathologically characterized matched donor brains.	Oakley DH et al.	—	2024	→
A Missense Variant in CASKIN1's Proline-Rich Region Segregates with Psychosis in a Three-Generation Family.	Wahbeh MH et al.	—	2023	→
Application-Oriented Bulk Cryopreservation of Human iPSCs in Cryo Bags Followed by Direct Inoculation in Scalable Suspension Bioreactors for Expansion and Neural Differentiation.	Meiser I et al.	—	2023	→
Elevated levels of FMRP-target MAP1B impair human and mouse neuronal development and mouse social behaviors via autophagy pathway.	Guo Y et al.	—	2023	→
Excitatory Neurons Derived from Human-Induced Pluripotent Stem Cells Show Transcriptomic Differences in Alzheimer's Patients from Controls.	Sagar R et al.	—	2023	→
Genetically modified cell spheroids for tissue engineering and regenerative medicine.	Jiang Z et al.	—	2023	→
Induction of dopaminergic neurons for neuronal subtype-specific modeling of psychiatric disease risk.	Powell SK et al.	—	2023	→
iPSC-derived reactive astrocytes from patients with multiple sclerosis protect cocultured neurons in inflammatory conditions.	Kerkering J et al.	—	2023	→
Mapping PTBP2 binding in human brain identifies SYNGAP1 as a target for therapeutic splice switching.	Dawicki-McKenna JM et al.	—	2023	→
Neurotransmitter release progressively desynchronizes in induced human neurons during synapse maturation and aging.	Uzay B et al.	—	2023	→
Non-additive effects of schizophrenia risk genes reflect convergent downstream function	Deans PM et al.	—	2023	—
Regulation of synaptic connectivity in schizophrenia spectrum by mutual neuron-microglia interaction.	Breitmeyer R et al.	—	2023	→
Reproducible Differentiation of Human Pluripotent Stem Cells into Two-Dimensional Cortical Neuron Cultures with Checkpoints for Success.	Waxman EA et al.	—	2023	→
TAT-LBD-Ngn2-improved cognitive functions after global cerebral ischemia by enhancing neurogenesis.	Feng B et al.	—	2023	→
The technology, opportunities, and challenges of Synthetic Biological Intelligence.	Kagan BJ et al.	—	2023	→
Transition from Animal-Based to Human Induced Pluripotent Stem Cells (iPSCs)-Based Models of Neurodevelopmental Disorders: Opportunities and Challenges.	Guerreiro S et al.	—	2023	→
Analysis of the circRNA and T-UCR populations identifies convergent pathways in mouse and human models of Rett syndrome.	Siqueira E et al.	—	2022	→
A translational genomics approach identifies IL10RB as the top candidate gene target for COVID-19 susceptibility.	Voloudakis G et al.	—	2022	→
Aβ42 oligomers trigger synaptic loss through CAMKK2-AMPK-dependent effectors coordinating mitochondrial fission and mitophagy.	Lee A et al.	—	2022	→
Combining NGN2 programming and dopaminergic patterning for a rapid and efficient generation of hiPSC-derived midbrain neurons.	Sheta R et al.	—	2022	→
Making neurons, made easy: The use of Neurogenin-2 in neuronal differentiation.	Hulme AJ et al.	—	2022	→
Modeling gene × environment interactions in PTSD using human neurons reveals diagnosis-specific glucocorticoid-induced gene expression.	Seah C et al.	—	2022	→
Topologically controlled circuits of human iPSC-derived neurons for electrophysiology recordings.	Girardin S et al.	—	2022	→
Analysis framework and experimental design for evaluating synergy-driving gene expression.	Schrode N et al.	—	2021	→
Cell type-specific changes in transcriptomic profiles of endothelial cells, iPSC-derived neurons and astrocytes cultured on microfluidic chips.	Middelkamp HHT et al.	—	2021	→
Differential acute impact of therapeutically effective and overdose concentrations of lithium on human neuronal single cell and network function.	Izsak J et al.	—	2021	→
Efficient Derivation of Excitatory and Inhibitory Neurons from Human Pluripotent Stem Cells Stably Expressing Direct Reprogramming Factors.	Song S et al.	—	2021	→
Fitness selection of hyperfusogenic measles virus F proteins associated with neuropathogenic phenotypes.	Ikegame S et al.	—	2021	→
<i>MED12</i>-Related (Neuro)Developmental Disorders: A Question of Causality.	Plassche SV et al.	—	2021	→
Improved Method for Efficient Generation of Functional Neurons from Murine Neural Progenitor Cells.	Soni A et al.	—	2021	→
Intronic enhancer region governs transcript-specific <i>Bdnf</i> expression in rodent neurons.	Tuvikene J et al.	—	2021	→
Modulating the Electrical and Mechanical Microenvironment to Guide Neuronal Stem Cell Differentiation.	Oh B et al.	—	2021	→
Physiological and Pathological Ageing of Astrocytes in the Human Brain.	Verkerke M et al.	—	2021	→
SOX9-induced Generation of Functional Astrocytes Supporting Neuronal Maturation in an All-human System.	Neyrinck K et al.	—	2021	→
Stem cell-derived neurons reflect features of protein networks, neuropathology, and cognitive outcome of their aged human donors.	Lagomarsino VN et al.	—	2021	→
Transformative Network Modeling of Multi-omics Data Reveals Detailed Circuits, Key Regulators, and Potential Therapeutics for Alzheimer's Disease.	Wang M et al.	—	2021	→
Using the dCas9-KRAB system to repress gene expression in hiPSC-derived <i>NGN2</i> neurons.	Li A et al.	—	2021	→
ASCL1- and DLX2-induced GABAergic neurons from hiPSC-derived NPCs.	Barretto N et al.	—	2020	→
Cell Type-Specific In Vitro Gene Expression Profiling of Stem Cell-Derived Neural Models.	Gregory JA et al.	—	2020	→
CRISPR-based functional evaluation of schizophrenia risk variants.	Rajarajan P et al.	—	2020	→
Doublecortin-like Kinase 1 Regulates α-Synuclein Levels and Toxicity.	Vázquez-Vélez GE et al.	—	2020	→
Emerging Developments in Human Induced Pluripotent Stem Cell-Derived Microglia: Implications for Modelling Psychiatric Disorders With a Neurodevelopmental Origin.	Hanger B et al.	—	2020	→
Global Landscape and Dynamics of Parkin and USP30-Dependent Ubiquitylomes in iNeurons during Mitophagic Signaling.	Ordureau A et al.	—	2020	→
High-throughput screening identifies histone deacetylase inhibitors that modulate GTF2I expression in 7q11.23 microduplication autism spectrum disorder patient-derived cortical neurons.	Cavallo F et al.	—	2020	→
Integrating CRISPR Engineering and hiPSC-Derived 2D Disease Modeling Systems.	Rehbach K et al.	—	2020	→
Investigation of Schizophrenia with Human Induced Pluripotent Stem Cells.	Powell SK et al.	—	2020	→
Modeling neuronal consequences of autism-associated gene regulatory variants with human induced pluripotent stem cells.	Ross PJ et al.	—	2020	→
Neuronal differentiation strategies: insights from single-cell sequencing and machine learning.	Konstantinides N et al.	—	2020	→
The innate immunity protein IFITM3 modulates γ-secretase in Alzheimer's disease.	Hur JY et al.	—	2020	→
Transcription Factor-Based Fate Specification and Forward Programming for Neural Regeneration.	Flitsch LJ et al.	—	2020	→
Direct Neuronal Reprogramming Reveals Unknown Functions for Known Transcription Factors.	Colasante G et al.	—	2019	→
Human iPSC application in Alzheimer's disease and Tau-related neurodegenerative diseases.	Tcw J	—	2019	→
<i>CNTN5</i><sup>-</sup><i><sup>/+</sup></i>or <i>EHMT2</i><sup>-</sup><i><sup>/+</sup></i>human iPSC-derived neurons from individuals with autism develop hyperactive neuronal networks.	Deneault E et al.	—	2019	→
Molecular Interaction Networks to Select Factors for Cell Conversion.	Ouyang JF et al.	—	2019	→
mTOR and autophagy pathways are dysregulated in murine and human models of Schaaf-Yang syndrome.	Crutcher E et al.	—	2019	→
Neuronal impact of patient-specific aberrant NRXN1α splicing.	Flaherty E et al.	—	2019	→
Overexpression of NEUROG2 and NEUROG1 in human embryonic stem cells produces a network of excitatory and inhibitory neurons.	Lu C et al.	—	2019	→
Robust Generation of Person-Specific, Synchronously Active Neuronal Networks Using Purely Isogenic Human iPSC-3D Neural Aggregate Cultures.	Izsak J et al.	—	2019	→
Synergistic effects of common schizophrenia risk variants.	Schrode N et al.	—	2019	→
Synthetic mRNAs Drive Highly Efficient iPS Cell Differentiation to Dopaminergic Neurons.	Xue Y et al.	—	2019	→
Best Practices for Translational Disease Modeling Using Human iPSC-Derived Neurons.	Engle SJ et al.	—	2018	→
Convergence of independent DISC1 mutations on impaired neurite growth via decreased UNC5D expression.	Srikanth P et al.	—	2018	→
Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells?	Prytkova I et al.	—	2018	→
Inhibition of STEP<sub>61</sub> ameliorates deficits in mouse and hiPSC-based schizophrenia models.	Xu J et al.	—	2018	→
Modeling Neuropsychiatric and Neurodegenerative Diseases With Induced Pluripotent Stem Cells.	LaMarca EA et al.	—	2018	→
Neuron-specific signatures in the chromosomal connectome associated with schizophrenia risk.	Rajarajan P et al.	—	2018	→
Application of CRISPR/Cas9 to the study of brain development and neuropsychiatric disease.	Powell SK et al.	—	2017	→
Discovery of Compounds that Positively Modulate the High Affinity Choline Transporter.	Choudhary P et al.	—	2017	→
Evaluating Synthetic Activation and Repression of Neuropsychiatric-Related Genes in hiPSC-Derived NPCs, Neurons, and Astrocytes.	Ho SM et al.	—	2017	→
Patient-derived hiPSC neurons with heterozygous CNTNAP2 deletions display altered neuronal gene expression and network activity.	Flaherty E et al.	—	2017	→
Personalized medicine in a dish: the growing possibility of neuropsychiatric disease drug discovery tailored to patient genetic variants using stem cells.	Brennand KJ	—	2017	→
Pluripotent stem cells in neuropsychiatric disorders.	Soliman MA et al.	—	2017	→
Prospects for Modeling Abnormal Neuronal Function in Schizophrenia Using Human Induced Pluripotent Stem Cells.	Prytkova I et al.	—	2017	→
Stem cell-derived neurons in the development of targeted treatment for schizophrenia and bipolar disorder.	Watmuff B et al.	—	2017	→
THC Treatment Alters Glutamate Receptor Gene Expression in Human Stem Cell-Derived Neurons.	Obiorah IV et al.	—	2017	→
Coenzyme A corrects pathological defects in human neurons of PANK2-associated neurodegeneration.	Orellana DI et al.	—	2016	→
Human pluripotent stem cells.	Carpenedo RL et al.	—	2016	→